- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05510622
Uterine Microbiome in Recurrent Pregnancy Loss
August 19, 2022 updated by: Mỹ Đức Hospital
Reproductive Tract Microbiome in Women With Recurrent Pregnancy Loss
The female genital tract microbiome may reflect female reproductive health and may be related to pregnancy outcomes.
Disturbances in this microbiome may be associated with adverse reproductive outcomes.
The investigators hypothesize that the endometrial and vaginal microbiome composition in women with a history of recurrent pregnancy loss are different, compared with those in normal fertile women.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
The investigators want to describe the endometrial microbiome composition in normal fertile women and women with a history of recurrent pregnancy loss by analyzing mid-luteal phase vaginal swab and endometrial biopsy samples using 16S rRNA sequencing.
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hieu LT Hoang, MD
- Phone Number: (+84) 969 166 318
- Email: bshieu.hlt@gmail.com
Study Contact Backup
- Name: Tuong M Ho, MD, MCE
- Phone Number: (+84) 903 633 377
- Email: bstuong.hm@myduchospital.vn
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 38 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Sampling Method
Probability Sample
Study Population
For RPL women: having ≥ 2 recurrent pregnancy loss.
For NF women: having ≥ 1 live birth after spontaneous conception, with no history of pregnancy loss
Description
Recurrent pregnancy loss patients
Inclusion Criteria:
- 18-38 years old
- Having a regular menstrual cycle, from 28 to 30 days
- Having ≥ 2 recurrent pregnancy loss and
- Couples with normal karyotype results
- Having no condition causing pregnancy loss such as antiphospholipid syndrome, abnormal thyroid function.
- Agree to participate in the study
Exclusion Criteria:
- Irregular menstrual cycle
- Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal fibroid)
- Using intrauterine device within the last 3 months
- Using antibiotic/vaginal pessary/contraceptive pills within 2 weeks
- Having sexual intercourse within 48 hours
- Healthy control patients
Inclusion Criteria:
- 18-38 years old
- Having a regular menstrual cycle, from 28 to 30 days
- No history of pregnancy loss
- Having 1 or more live birth, with the youngest child ≥ 6 months old
- Agree to participate in the study
Exclusion Criteria:
- Irregular menstrual cycle
- Having uterine abnormalities (e.g., adenomyosis, intrauterine adhesions, unicornuate/ bicornuate/ arcuate uterus; unremoved hydrosalpinx, endometrial polyp, submucosal fibroid)
- Using intrauterine device within the last 3 months
- Using antibiotic/vaginal pessary/contraceptive pills within 2 weeks
- Having sexual intercourse within 48 hours
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Recurrent pregnancy loss
Women with history of recurrent pregnancy loss
|
A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
|
Control
Normal fertile women
|
A vaginal swab (DNA/RNA shield collection tube with swab - Zymo Research, CatNo R1107) and endometrial biopsy (Endobrush® - Lab CCD, Paris, France) will be obtained during 18th - 22nd day of the menstrual cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Midluteal bacterial composition of endometrium in women with recurrent pregnancy loss and control group
Time Frame: 1 week
|
Bacterial composition in the endometrium in midluteal phase are analysed using 16S rRNA gene sequencing
|
1 week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Midluteal bacterial composition of vagina in women with recurrent pregnancy loss and control group
Time Frame: 1 week
|
Bacterial composition in the vaginal in midluteal phase are analysed using 16S rRNA gene sequencing
|
1 week
|
Phylogenetic tree of endometrial microorganisms in women with recurrent pregnancy loss and control group
Time Frame: 1 week
|
Phylogenetic tree based on 16S rRNA gene sequences
|
1 week
|
Phylogenetic tree of vaginal microorganisms in women with recurrent pregnancy loss and control group
Time Frame: 1 week
|
Phylogenetic tree based on 16S rRNA gene sequences
|
1 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Lan N Vuong, MD, PhD, University of Medicine and Pharmacy at Ho Chi Minh City
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
August 20, 2022
Primary Completion (ANTICIPATED)
December 30, 2023
Study Completion (ANTICIPATED)
June 30, 2024
Study Registration Dates
First Submitted
August 13, 2022
First Submitted That Met QC Criteria
August 19, 2022
First Posted (ACTUAL)
August 22, 2022
Study Record Updates
Last Update Posted (ACTUAL)
August 22, 2022
Last Update Submitted That Met QC Criteria
August 19, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05/22/DD-BVMD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaginal Microbiome
-
University Hospital, AntwerpRecruitingSkin Microbiome | Vaginal Microbiome | Saliva MicrobiomeBelgium
-
Hillel Yaffe Medical CenterUnknown
-
Vanderbilt University Medical CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCesarean Section | Microbiome | Vaginal Seeding | NoseUnited States
-
Peking Union Medical College HospitalNot yet recruitingVaginal Microbiome | Graft Versus Host Reaction
-
Copenhagen University Hospital, HvidovreCompletedTransplantation | Vaginal Dysbiosis | Vaginal MicrobiomeDenmark
-
Kinderwunsch Institut GmbHInstitut AllergoSanCompleted
-
National Institute of Allergy and Infectious Diseases...TerminatedVaginal Candidiasis | Microbiome | Antibiotic-Induced VVCUnited States
-
Medical University of ViennaUniversity of ViennaUnknown
-
ProgenaBiomeRecruitingGastrointestinal Microbiome | Gut MicrobiomeUnited States
Clinical Trials on Vaginal swab and endometrial biopsy
-
University Hospital, GhentCenter for Microbial Ecology and Technology - Ghent UniversityCompletedRepeated Implantation Failure | Normal FertileBelgium
-
Cairo UniversityCompletedFirst Trimester AbortionEgypt
-
Jon HavelockTerminatedInfertility | PregnancyCanada
-
Anne's Day LtdCareggi Hospital; Lindus HealthActive, not recruitingChlamydia | Gonorrhea | Human Papilloma Virus | Bacterial VaginosisUnited Kingdom
-
Cook Group IncorporatedTerminatedUterine Neoplasms | Polycystic Ovary Syndrome | Endometrial Neoplasms | MenorrhagiaPanama
-
University of PittsburghMerck Sharp & Dohme LLCCompletedInflammatory Bowel Disease (IBD) | Ulcerative Colitis (UC) | Crohn's Disease (CD) | Anal Human PapillomavirusUnited States
-
Centre Hospitalier Universitaire de NīmesWithdrawnInfertility | Abortion, Spontaneous | Embryo Implantation, DelayedFrance
-
University of LuebeckRecruitingSexually Transmitted InfectionGermany
-
University Hospital, GenevaCompletedHuman Papillomavirus InfectionSwitzerland
-
The University of Texas Health Science Center at...CompletedCandidiasis | Vaginitis | Vaginosis, Bacterial | Vaginal Discharge | TrichomonasUnited States